Platelet rich plasma, osteoarthritis, thumb base, pain Platelet rich plasma, joint degeneration, thum base, pain
Conditions
Interventions
Sponsors
GOED Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age 18 or older Patients with an Eaton-littler score of I, II or IIIPatients with uni- or bilateral CMC-I osteoarthritisNon-responders to conservative therapy i.e., hand therapy and immobilisation after 3 months
Exclusion criteria
Exclusion criteria: Aged below 18Patients with an Eaton-littler score of IV (STT arthrosis)Surgical interventions of the CMC-I joint A known articular systemic disease (e.g. rheumatoid arthritis) or additional hand osteoarthritis/ tenosynovitis or metabolic disease like diabetes mellitus Patients with an infectious arthritis of CMC-I joint A known psychiatric conditionChronic pain syndromeIntra articular injection 6 months prior to inclusion Smoking Active use of statins
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to quantify clinical improvement of pain caused by CMC-I osteoarthritis. The comparison is done using a dVAS score for pain (least pain 0-10 most pain). Patients will complete the dVAS score preoperatively and 3 months, 6 months, 9 months, and 12 months postoperative. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective of this study is to quantify functional improvement of CMC-I osteoarthritis. The comparison is done using the MHQ-DLV questionnaire. Patients will complete the MHQ-DLV questionnaires preoperatively and 3 months, 6 months, 9 months, and 12 months postoperative. Ultrasound control of the articular space will be performed to inspect signs of synovitis preoperatively, 3 months, 6 months, 9 months, and 12 months postoperative. To quantify functional improvement of CMC-I osteoarthritis by PRP as injectable in comparison to saline, thumb strength and motion will be tested. Strength will be tested with grip strength and pinch test. Motion will be tested with opposition of the thumb (pollexograph) and palmar abduction as well as preoperatively and 3 months, 6 months, 9 months, and 12 months. Data regarding thrombocyte and leukocyte count in blood samples and PRP will be evaluated. | — |
Countries
Netherlands
Contacts
Public ContactJA Dongen
GOED Medisch Centrum
Outcome results
None listed